33 results about "Cyclophilin A" patented technology

The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to at least one binding site of Cyclophilin A on the HIV capsid protein. (SEQ ID NOS: 2, 4, and 6) The present invention contemplates three categories of embodiments: protein or protein fragments (SEQ ID NOS: 2, 4, and 6), messenger RNA, or DNA / RNA. DNA / RNA compositions (SEQ ID NOS 1, 3, 5, 7, 9, and 11) may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants.

The present invention constructs red ray (Dasytis akajei) tail thorn cDNA library and DNA sequencing, and according to the obtained cyclophilin (CyP) EST 3' end and carrier nucleotide sequence, designs primers, uses the method of PCR, from The full-length cyclophilin A gene was screened and cloned from the red ray sting cDNA library. The length of the new gene is 656bp, and it encodes a mature peptide of 167 amino acids. The expressed protein has an isoelectric point of 8.34 and a molecular weight of about 18,021 Daltons. The red stingray thorn cyclophilin A gene was cloned at the 3' end of the trxA gene of the thioredoxin gene fusion expression vector pTRX, and a fusion gene in line with the reading frame was constructed. The fusion protein was soluble in E. coli as an intracellular Form exists, the expression amount can reach 60mg / L. Through Ni-Chelating affinity chromatography, protease 3C cleavage and gel filtration, the mature recombinant red ray cyclophilin A protein with a purity of more than 95% was obtained, with a yield of 10 mg / L. The protein has peptidylproline cis-trans isomerase activity.

The invention discloses a Rotavirus-resistant drug acting target which is a composite three-dimensional structure model of interaction of rotavirus VP6 protein and human Cyclophilin A, wherein the functional zone of the VP6 protein is amino acid from 52th to 100th site and amino acid from 349th to 392th site, and the active site comprises Asn 53, Ala 348, Val 349, Ile 355 and Pro 363; and the functional zone of the Cyclophilin A is amino acid from 54th to150th site, and the active site comprises Arg 55, Gln 63, Lys 125 and Arg 148. The invention also discloses a building method and an application method of the target; and the target and the application method thereof can simply and fast screen or design a compound capable of blocking the interaction of the rotavirus VP6 protein and the human Cyclophilin A; the invention researches and develops a specificity Rotavirus-resistant drug which is efficient and harmfulless; and the building method of the target is favor of the building of acting targets of other drugs.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The inventio discloses a hybridoma cell, a monoclonal antibody for anti-human cyclophilin A and an application thereof. The invention adopts a traditional cell hybridoma preparation technique for acquiring a hybridoma cell strain for stably secreting the monoclonal antibody of the anti-human cyclophilin A (cyclophilin A, CypA). The preservation number of the hybridoma cell is CCTCC NO: C201126; the secreted antibody can specifically identify CypA protein molecules expressed in various tissues of a human body; and a new effective tool is provided for diagnosing and treating cancers and inflammations.

The invention discloses a kit for specific detection of endometrial cancer. An aptamer provided in the invention has good affinity to human Cyclophilin A protein. Cyclophilin A protein in blood can be captured through the aptamer, and endometrial cancer can be detected through content variation of Cyclophilin A protein. The aptamer is prepared into a corresponding kit to be used for screening of endometrial cancer. The kit has the advantages of high sensitivity and low cost.

The invention discloses a kit for specific detection of endometrial carcinoma. An aptamer has high affinity to human Cyclophilin A protein. By utilizing the aptamer, the Cyclophilin A protein in blood can be captured, and the endometrial carcinoma is detected through changes in content of the Cyclophilin A protein; after the aptamer is prepared to be the corresponding kit which is about to be used for screening the endometrial carcinoma. The kit has the advantages high sensitivity and low cost.

The invention discloses a kit for specific detection on endometrial cancer. The aptamer disclosed by the invention has relatively good affinity with human Cyclophilin A protein. By adoption of the aptamer disclosed by the invention, Cyclophilin A protein in blood can be captured, endometrial cancer can be detected according to variation of the content of the Cyclophilin A protein, and a corresponding kit can be prepared to screen endometrial cancer. The kit disclosed by the invention has the advantages of high sensitivity and low cost.